cyc 202 has been researched along with adenosine in 5 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (adenosine) | Trials (adenosine) | Recent Studies (post-2010) (adenosine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 32,536 | 1,075 | 8,930 |
| Protein | Taxonomy | cyc 202 (IC50) | adenosine (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 0.3851 | |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.5 | |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | 5.5 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.0011 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0023 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 63 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Atrash, B; Barlow, C; Eccles, S; Fischer, PM; Hayes, A; Jackson, W; Jarman, M; Kelland, L; McDonald, E; Mirza, A; Moreno, J; Nutley, BP; Raynaud, FI; Sheldrake, P; Walton, M; Westwood, R; Whittaker, S; Wilson, SC; Workman, P | 1 |
| Behrens, C; Dmitrovsky, E; Freemantle, S; Heymach, JV; Hong, S; Hu, S; Johnson, FM; Kawakami, M; Lee, JJ; Liu, X; Mino, B; Mustachio, LM; Myung, JH; Rodriguez-Canales, J; Roszik, J; Tong, P; Villalobos, PA; Wang, J; Wistuba, I; Zheng, L | 1 |
| Blake, D; Chen, R; Chen, Y; Keating, MJ; Plunkett, W; Wierda, WG; Xiong, P; Zheleva, D | 1 |
5 other study(ies) available for cyc 202 and adenosine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Topics: Adenosine; Animals; Antineoplastic Agents; Cyclin-Dependent Kinases; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Purines; Roscovitine; Xenograft Model Antitumor Assays | 2011 |
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
Topics: Adenosine; Anaphase; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Centrosome; Cyclin-Dependent Kinase 2; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Purines; Roscovitine; Signal Transduction | 2017 |
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
Topics: Adenosine; Apoptosis; Apoptosis Regulatory Proteins; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Roscovitine; Sulfonamides; Tumor Microenvironment | 2022 |